Research and Markets: Pharmaceutical Industry in the United States: Industry Analysis, Forecast, Competition Mapping and Market Trends Assessment, 2011-2015

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/d810a8/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in the United States: Industry Analysis, Forecast, Competition Mapping and Market Trends Assessment, 2011-2015" report to their offering.

The United States spends more than any other country in the world on healthcare, at an estimated 16% of GDP in 2010. Healthcare expenditure is likely to continue to grow at a faster pace than overall GDP, so that its share in GDP is likely to continue to rise. In March 2010president Barack Obama signed into law a wide-ranging package of healthcare reforms, which extends insurance to around 45.7 million residents without health insurance cover.

These reforms are still encountering strong opposition, however, while another major challenge, the long-term costs of the public healthcare programs in the context of an ageing society, has not yet been addressed. Vested interests and conflicting objectives of cost-cutting and raising coverage make healthcare a particularly difficult policy issue.

This report analyses the U.S. pharmaceutical industry, its historical performance and future trends for various segments as well as the overall market.

Competitive analysis of leading companies is presented with focus on threats from generics. Supply chain analysis of the U.S. pharmaceutical industry is given in detail. Also covered are the market trends, growth drivers and constraints, and an assessment of M&A activity in recent years.

Key Report Takeaways: U.S. healthcare spending in 2010 was US$2.3 trillion or 16% of GDP, more than any other country in the world. United States is the largest pharmaceutical market globally, with 2010 sales of US$307 billion or 40% of global sales. In 2010, U.S. pharmaceutical sales grew at 2.3%; and since 2001 market has grown at a CAGR of 6.6%. Brand drugs losing patent protection and exclusivity resulted in the reduction in sales of US$12.6 billion while the sales of generics increased by US$7.6 billion. Top 5 therapeutic classes accounted for one-third of total sales, lead by Oncologics (US$22.3 billion), respiratory agents (US$19.3 billion), lipid regulators (US$18.7 billion), antidiabetes (US$16.9 billion) and antipsychotics (US$16.1 billion).

Key Topics Covered:

U.S. Healthcare Sector

Industry Overview

Generic Drugs Market Assessment

Distribution and Supply Chain Analysis

Trend Analysis

Growth Drivers and Constraints

Government Policies and Regulations

Competitive Landscape

Mergers & Acquisitions Assessment

Companies Mentioned:

Pfizer Inc.

Merck & Co., Inc.

AstraZeneca Plc

Novartis AG

Eli Lilly & Co.

For more information visit http://www.researchandmarkets.com/research/d810a8/pharmaceutical_ind

Research and MarketsLaura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Source: Research and Markets